Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ra Medical Systems to Report First Quarter 2022 Financial Results on May 16, 2022

RMED

Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report financial results for the three months ended March 31, 2022 after market close on Monday, May 16. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

Pre-Registration

Participants can pre-register for the conference call here:

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Live Call:

Those who choose not to pre-register can access the live conference by dialing:

U.S.

866-777-2509

International

412-317-5413

Request to join the Ra Medical Systems conference call

Live Webcast:

Ra Medical Systems Website

The webcast will be archived for 30 days.

Replay:

U.S.

877-344-7529

Canada

855-669-9658

International

412-317-0088

Passcode

6866135

The replay will be available for 48 hours

About Ra Medical Systems

Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of certain vascular diseases. DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.

Tags: